- Home
- DXLG vs MGX Comparison
DXLG vs MGX Comparison
Compare DXLG & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- MGX
- Stock Information
- Founded
- DXLG 1976
- MGX 2018
- Country
- DXLG United States
- MGX United States
- Employees
- DXLG N/A
- MGX N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- MGX
- Sector
- DXLG Consumer Discretionary
- MGX
- Exchange
- DXLG Nasdaq
- MGX NYSE
- Market Cap
- DXLG 64.0M
- MGX 62.1M
- IPO Year
- DXLG 1987
- MGX 2024
- Fundamental
- Price
- DXLG $1.15
- MGX $1.58
- Analyst Decision
- DXLG Strong Buy
- MGX Strong Buy
- Analyst Count
- DXLG 1
- MGX 4
- Target Price
- DXLG $2.50
- MGX $13.00
- AVG Volume (30 Days)
- DXLG 632.5K
- MGX 657.9K
- Earning Date
- DXLG 05-29-2025
- MGX 08-13-2025
- Dividend Yield
- DXLG N/A
- MGX N/A
- EPS Growth
- DXLG N/A
- MGX N/A
- EPS
- DXLG N/A
- MGX N/A
- Revenue
- DXLG $457,059,000.00
- MGX $45,263,000.00
- Revenue This Year
- DXLG N/A
- MGX N/A
- Revenue Next Year
- DXLG $3.56
- MGX $11.75
- P/E Ratio
- DXLG N/A
- MGX N/A
- Revenue Growth
- DXLG N/A
- MGX N/A
- 52 Week Low
- DXLG $0.90
- MGX $1.23
- 52 Week High
- DXLG $3.93
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- DXLG 49.13
- MGX 51.92
- Support Level
- DXLG $0.98
- MGX $1.41
- Resistance Level
- DXLG $1.09
- MGX $1.59
- Average True Range (ATR)
- DXLG 0.07
- MGX 0.12
- MACD
- DXLG -0.00
- MGX 0.00
- Stochastic Oscillator
- DXLG 36.40
- MGX 47.62
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.